Speech-in-noise Perception in Autism and Fragile X
Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · Oct 12, 2023
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how the brain processes speech when there is background noise, particularly in individuals with Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS). Researchers want to find out which areas of the brain are active during these situations and whether visual cues, like lip movements or gestures, can help people understand speech better when there's noise around them. Participants will undergo hearing tests, complete questionnaires about their symptoms, and perform tasks while their brain activity is monitored.
To join the study, individuals should be between the ages of 5 and 18, have normal hearing and vision, and speak English as their first language. Those with ASD must have a confirmed diagnosis, while participants with FXS need to have genetic testing that shows they have the condition. The study is currently looking for participants, and it’s important to note that those with hearing loss or certain other medical conditions won’t be eligible. Overall, this trial aims to improve our understanding of how these conditions affect communication in noisy environments, which might help develop better support strategies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. normal audiograms (PTA ≤ 20 dB HL)
- • 2. corrected 20/20 vision (Snellen chart)
- • 3. no history of premature birth (prior to 36 weeks gestation)
- • 4. no medications known to affect EEG signal
- • 5. English as the first language
- Inclusion for the Autism group requires the following:
- • 1) diagnosis of Autism Spectrum Disorder either based on previous ADOS administration and developmental history, or confirmed via ADOS and developmental history
- Inclusion for the Autism + FXS group requires the following:
- • 1. Documented PCR/Southern Blot genetic testing confirming full mutation FXS
- • 2. Diagnosis of Autism Spectrum Disorder, per Autism group.
- Inclusion for the Typically Developing group requires the following:
- • 1. no siblings or parents with an Autism Spectrum Disorder or Fragile X Syndrome
- • 2. no current neurological or psychiatric diagnoses
- • 3. IQ over 75
- Exclusion Criteria:
- • Hearing loss or uncorrected vision loss
- • history of premature birth (prior to 36 weeks gestation)
About Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center in Cincinnati is a leading pediatric healthcare institution dedicated to advancing child health through innovative clinical research and comprehensive patient care. Renowned for its commitment to excellence, the center conducts a wide range of clinical trials aimed at developing and evaluating new treatments and therapies for pediatric populations. With a focus on multidisciplinary collaboration and ethical research practices, Children's Hospital Medical Center strives to improve health outcomes for children while contributing to the broader scientific understanding of pediatric medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Patients applied
Trial Officials
Elizabeth Smith, PhD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported